Additional acquisitions will spread the cash focus too thin, meaning targets will not be tested effectively. Will be interesting to see how they plan to focus these funds. MC is abysmal.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025